Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandiah, Nagaendran, Pai, Ming-Chyi, Senanarong, Vorapun, Looi, Irene, Ampil, Encarnita, Park, Kyung Won, Karanam, Ananda Krishna, Christopher, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402908/
https://www.ncbi.nlm.nih.gov/pubmed/28458525
http://dx.doi.org/10.2147/CIA.S129145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402908/
https://www.ncbi.nlm.nih.gov/pubmed/28458525
http://dx.doi.org/10.2147/CIA.S129145

Ejemplares similares